Cartalax dose guide

Cartalax dosage

A short peptide from the Russian bioregulator program behind Epitalon and Pinealon, which its developers describe as a bioregulator for cartilage and joints. In cell studies it raised the genes cartilage is built from in aging stem cells and damped the aging signals of cartilage cells, and in rats it slowed bone loss. No human study has been published, and nearly all the research is by its developers. Commonly reported: easier, less stiff joints over a few weeks for some, quick relief for a few and nothing at all for others; it is often added to BPC-157 and TB-500 or the KLOW blend.

Dose range

No reference dose. No human study has tested a dose of Cartalax: the amounts people run are their own protocol, not a reference.

How often

Daily

A typical run

Courses of 10–30 days (community practice). Run in courses rather than continuously, like the other bioregulators. Its developers' capsules are labelled for a one-month course, repeated after 3–6 months; injected courses commonly run 10–20 days, a few times a year, and some run for weeks longer. No study has tested a course length.

How it’s taken

Vial: SubQ injection, Oral capsules

Evidence

Emerging: Primarily preclinical / limited human data

Half-life

Unknown (never measured)

Cartalax on your syringe

The library carries no reference dose for it, so there’s no range to put on a syringe.

Cartalax in the peptide libraryThe Dose Guide: every peptide

More healing peptides

• BPC-157 200–500 mcg
• TB-500 1–2.5 mg
• GHK-Cu 1–2 mg
• KPV 100–300 mcg
• AOD-9604 250–300 mcg
• Thymosin Alpha-1 1–1.6 mg
• Thymosin Beta-4 2–2.5 mg
• LL-37 100–300 mcg
• Larazotide 0.5–1 mg
• VIP 50 mcg
• ARA-290 1–4 mg
• Ac-SDKP 250–750 mcg

A community reference, not medical advice. Each range is what has been studied or is commonly run, never a dose for you.